The U.S. administration of President Donald Trump has revoked Executive Order 14081, “Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy,” originally issued on September 12, 2022. This decision will have far-reaching consequences for the U.S. biotech industry.
Brainomix Ltd. completes £14m Series C financing
Latest NewsUniversity of Oxford spinout Brainomix Ltd has closed a £14m Series C round to advance its commercial expansion in the US. Funding will also support clinical uptake of its AI imaging technology in stroke and lung fibrosis.
US President deprioritises biotechnology
Latest NewsThe U.S. administration of President Donald Trump has revoked Executive Order 14081, “Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy,” originally issued on September 12, 2022. This decision will have far-reaching consequences for the U.S. biotech industry.
Sofinnova Partners closes €165m Biovelocita II biotech acceleration fund
Latest NewsSofinnova Partners has raised €165m within its biotech acceleration fund Biovelocita II that attracted investments fromBig Pharma including Amgen, Bristol Myers Squibb, and Pfizer Ventures.
Poland breaks opposition to EU NGT deregulation
Latest NewsAt the third attempt, the Polish Council Presidency has broken the resistance of the member states against the deregulation of crops produced by new genomic technologies (NGT). The new draft will enter trilogue discussions in April.
SpliceBio lauches Phase I/II study on dual-AAV-based therapy for Stargardt Disease
Latest NewsSpanish SpliceBio has dosed the first patient with SB-007, the first dual AAV gene therapy in clinical development for Stargardt disease
Regulatory sandbox will speed up safety assessment of cell-based food
Latest NewsThe UK Food Standards Agency (FSA) has selected eight companies to participate in a two-year regulatory programme set to speed up market approval and safety assessment of cell-cultivated products.
Roche inks US$1.65bn obesity deal with Zealand Pharma
Latest NewsRoche is extending its obesity pipeline signing a US$5.3bn biobucks deal with Zealand Pharma A/S, who will co-develop and co-commercialise a monotherapy of its long-acting amylin analogue petrelintide with the Swiss pharma giant in the US and Europe and do the same for a combo of petrelintide and Roche’s GLP1/GIP receptor agonist CTT388.
Gilead’s Capsid Revolution Meets Our Capsid Solutions: Sino Biological – Engineering the Tools to Outsmart HIV
slider, Sponsored PublicationsHigh-Quality HIV Antigens for Cutting-Edge Solutions
Novo Nordisk’s obesity drug CagriSema disappoints again
Latest NewsNovo Nordisk A/S’ combined GLP1-, amylin- and calcitonin receptor agonist CagriSema has failed to meet the expected 25% weight loss within 68 weeks in the second of four pivotal Phase III trials. Shares in Novo Nordisk closed down 8% after the data became public.
15th European Biotechnology Science & Industry Guide 2025
ProductsThe 15th edition of the European Biotechnology Science & Industry Guide is showcasing brilliant science and excellent business from companies, universities, research institutes, and expert support providers. In addition to the detailed portraits on 176 colored pages, the guide features a report about sustainability and the biologisation of industrial production. Readers will discover many success stories and current trends in the European biotech industry.